Stay updated on Nivolumab & Ibrutinib in CNS Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab & Ibrutinib in CNS Lymphoma Clinical Trial page.

Latest updates to the Nivolumab & Ibrutinib in CNS Lymphoma Clinical Trial page
- Check3 days agoChange DetectedAdded a 'Locations' section that includes Texas as a study site. The older 'Texas Locations' label was removed and the HHS Vulnerability Disclosure link was deleted in this revision.SummaryDifference0.2%

- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing Revision: v3.3.1.SummaryDifference0.1%

- Check31 days agoChange DetectedPublications section updated from 'No Results Posted' to 'Results Submitted', with an explanatory note that PubMed-listed publications are automatically filled from PubMed and may not be about the study.SummaryDifference0.2%

- Check38 days agoChange DetectedRemoved the government funding lapse notice from the page. This is an administrative update that does not pertain to the study details.SummaryDifference0.4%

- Check53 days agoChange DetectedPublications section updated with the 2025 Blood Advances article detailing the phase 2 trial of ibrutinib and nivolumab in relapsed CNS lymphoma. The study record shows a last update posted on 2025-02-28.SummaryDifference0.4%

- Check81 days agoChange DetectedMajor update to the page content: a government-operating status notice and a new version tag (v3.2.0) replacing v3.1.0.SummaryDifference3%

Stay in the know with updates to Nivolumab & Ibrutinib in CNS Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab & Ibrutinib in CNS Lymphoma Clinical Trial page.